Weekly Cardiology Research Analysis
This week cardiology research emphasized actionable shifts in care: a randomized ECMO anticoagulation trial (RATE) supports lower-intensity strategies that reduce bleeding without increasing thrombosis; PET-guided comprehensive CAD management (CENTURY) demonstrated reduced death, MI and revascularization using physiology-directed prevention and selective revascularization; and mechanistic work (Bclaf1–Srsf2–Hand2) revealed a splicing axis driving HFrEF that nominates new therapeutic nodes. Acros
Summary
This week cardiology research emphasized actionable shifts in care: a randomized ECMO anticoagulation trial (RATE) supports lower-intensity strategies that reduce bleeding without increasing thrombosis; PET-guided comprehensive CAD management (CENTURY) demonstrated reduced death, MI and revascularization using physiology-directed prevention and selective revascularization; and mechanistic work (Bclaf1–Srsf2–Hand2) revealed a splicing axis driving HFrEF that nominates new therapeutic nodes. Across papers, trends include scalable EHR diagnostics, proteomic and imaging prognostic tools, and genotype/phenotype–directed therapies.
Selected Articles
1. Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.
RATE, a multicenter randomized non-inferiority trial in ECMO patients, found low-dose UFH and therapeutic LMWH non-inferior to standard-dose UFH for a composite of severe bleeding, severe thromboembolism, or 6‑month mortality. Lower-intensity approaches trended to fewer severe bleeding events without excess thrombosis, supporting re-evaluation of anticoagulation targets in ECMO care.
Impact: First adequately powered randomized evidence to reconsider anticoagulation intensity on ECMO, with immediate implications to reduce bleeding harm while maintaining thrombotic protection.
Clinical Implications: Centers can consider implementing lower-intensity anticoagulation protocols (low-dose UFH or therapeutic LMWH) with careful monitoring to reduce bleeding risk; update ECMO guidelines and local protocols pending broader replication.
Key Findings
- Low-dose UFH and therapeutic LMWH were non-inferior to standard-dose UFH for the composite endpoint (severe bleeding, severe thromboembolism, or 6‑month mortality).
- Numerically fewer severe bleeding events occurred with low-dose UFH and LMWH versus standard UFH without excess thromboembolic complications.
- This is a multicenter randomized trial with prespecified non-inferiority margins and intention-to-treat analysis.
2. Quantitative PET coronary flow capacity and comprehensive management of chronic CAD: Lessons from the randomized CENTURY trial.
CENTURY randomized 1,028 patients to PET-derived coronary flow capacity (CFC)-guided comprehensive care versus standard community cardiologist–directed care. CFC-guided integrated lifestyle, medical therapy, and selective revascularization for severely reduced CFC reduced all-cause death, death or MI, late revascularization, and MACE at 5 years, with sustained benefits linked to adherence to risk-factor control.
Impact: A rigorously conducted randomized trial demonstrating that physiology-guided, integrated prevention with selective revascularization lowers hard outcomes in chronic CAD, potentially redefining care pathways.
Clinical Implications: Implement programs combining quantitative PET CFC phenotyping with intensive lifestyle and medical management, reserving angiography/revascularization for severe CFC, and ensure structured follow-up/support to sustain risk-factor control.
Key Findings
- Comprehensive PET-CFC guided care reduced all-cause mortality (4.7% vs 8.2%), death or MI (7.0% vs 11.1%), late revascularization (9.6% vs 14.8%), and MACE (20.5% vs 29.9%) at 5 years versus standard care.
- Only 5.4% underwent early revascularization within 90 days guided by severe CFC, enabling safe emphasis on prevention.
- Adherence intensity to risk-factor control over 5 years correlated with additional reductions in events over extended follow-up.
3. Bclaf1 drives heart failure by recruiting Srsf2 to enhance Hand2 pre-mRNA splicing and pathological hypertrophy.
This mechanistic study shows elevated Bclaf1 in human HFrEF and mouse pressure-overload models; cardiac Bclaf1 overexpression induces pathological hypertrophy and systolic dysfunction by recruiting Srsf2 to enhance Hand2 pre-mRNA splicing. Genetic or AAV9-mediated suppression of Bclaf1 or Hand2 rescues remodeling, identifying a druggable splicing axis for HFrEF.
Impact: Uncovers a previously unrecognized splicing-driven mechanism of HFrEF with clear upstream (Bclaf1/Srsf2) and downstream (Hand2) nodes that are amenable to therapeutic development.
Clinical Implications: Preclinical but high translational potential: motivates development of splicing-targeted therapeutics (antisense, small molecules) and early-phase trials assessing disease-modifying effects in HFrEF.
Key Findings
- Bclaf1 expression is elevated in human HFrEF myocardium and pressure-overload mouse hearts.
- Cardiac Bclaf1 overexpression causes pathological hypertrophy and systolic dysfunction; knockout or knockdown attenuates these phenotypes.
- Bclaf1 interacts with Srsf2 to enhance Hand2 pre-mRNA splicing, increasing mature Hand2 and driving maladaptive remodeling; inhibiting Bclaf1 or Hand2 rescues function.